Strategic question
A global re-insurer wanted to identify mature ventures across non-fluid underwriting, digital biomarkers, digital therapeutics, genomics and teleconsultation
How Galen Growth helped
From market signal to decision-ready evidence
Galen Growth combined HealthTech Alpha intelligence with structured ecosystem mapping to assess the relevant markets, ventures, and evidence against the client's decision criteria.
Outcomes
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Sourcing OMICS Ventures to Shape Oncology and Wellness Strategy
Which OMICS-led ventures tackling oncology and wellness are mature enough to partner with an enterprise insurer?
Sourcing HealthTech Ventures to Power Non-Fluid Underwriting
Which ventures across digital biomarkers, DTx, genomics and teleconsultation are mature enough to enable non-fluid underwriting?
Pressure-Testing a Digital Health Partnership Before Commitment
How does our preferred venture partner compare against credible alternatives in the same market and therapeutic focus?